DL-2-甲基安非他明盐酸盐 | 77083-24-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: DL-2-甲基安非他明盐酸盐
• 英文名称: Ortetamine Hydrochloride
• 英文别名: 1-(2-methylphenyl)propan-2-amine;hydrochloride
• CAS: 77083-24-0
• 化学式: C10H16ClN
• mdl: MFCD12197364
• 分子量: 185.69
• InChiKey: PIJNEJGPRPNSAE-UHFFFAOYSA-N

物化性质

• 溶解度：
  DMF：30mg/mL； DMSO：30mg/mL；乙醇：20mg/mL； PBS（pH 7.2）：10 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.32
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
  申请人：Pharmacia Corporation

  公开号：US20040176378A1

  公开（公告）日：2004-09-09

  The present invention provides compositions and methods for the treatment of reduced blood flow to the central nervous system in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition comprising the administration to a subject of an amphetamine in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了一种用于治疗主体中心神经系统血流量减少的组合物和方法。更具体地，本发明提供了一种中枢神经系统缺血症的组合治疗方法，包括向主体注射苯丙胺和环氧合酶-2选择性抑制剂。
• Ascending-dose dosage form
  申请人：ALZA CORPORATION

  公开号：EP1782798A2

  公开（公告）日：2007-05-09

  A dosage form and a method are disclosed for delivering to a human patient a drug in an ascending amount over time. In particular, the invention provides a dosage form having a length greater than its width, the dosage form comprising: (a) a first layer comprising 10 ng to 700 mg of a drug selected from methylphenidate or a pharmaceutically acceptable salt thereof; (b) a second layer comprising 80% to 95% of a hydrophilic-expandable polymer; (c) a wall comprising a semipermeable composition that surrounds the first and second layer; (d) an exit in the wall communicating with the first layer for delivering the drug; and wherein the dosage form when in operation administers the drug in an ascending rate over time.

  本发明公开了一种剂型和一种方法，用于向人类患者递送随时间递增的药物。特别是，本发明提供了一种长度大于宽度的剂型，该剂型包括 (a) 第一层，包含 10 毫微克至 700 毫克选自哌醋甲酯或其药学上可接受的盐的药物； (b) 第二层，包括 80%至 95%的亲水性可膨胀聚合物； (c) 包含半透性成分的壁，环绕第一层和第二层； (d) 壁中与第一层相通的出口，用于递送药物；以及其中的剂型在使用时以随时间递增的速率递送药物。
• Compositions and methods for liver growth and liver protection
  申请人：Genentech, Inc.

  公开号：EP2430923A1

  公开（公告）日：2012-03-21

  The present invention provides pharmaceutical compositions and methods for liver proliferation and protection. Specifically useful are VEGFR modulating agents capable of promoting liver growth. Disclosed compositions and methods may be useful for promoting proliferation or treating pathological conditions in other organs of significant biological functions.

  本发明提供了用于肝脏增殖和保护的药物组合物和方法。特别有用的是能够促进肝脏生长的血管内皮生长因子受体（VEGFR）调节剂。所公开的组合物和方法也可用于促进其他具有重要生物功能的器官的增殖或治疗病理状况。
• Pharmaceutical compositions and uses thereof
  申请人：Embera NeuroTherapeutics, Inc.

  公开号：US11179377B2

  公开（公告）日：2021-11-23

  Provided are pharmaceutical compositions useful for the treatment and/or prevention of a disorder, such as addiction. For example, pharmaceutical compositions are provided that comprise a first active pharmaceutical component (e.g., metyrapone) and a second active pharmaceutical component (e.g., oxazepam). The compositions may be constructed in such a manner as to limit the physical contact between the first and second active pharmaceutical components, thus preventing any degradation of the active pharmaceutical components resulting form interaction between the two components. The compositions may include at least one pharmaceutically acceptable excipient. Also provided are methods of making the compositions as well as kits containing materials to provide the compositions.

  本文提供的药物组合物可用于治疗和/或预防成瘾等疾病。例如，所提供的药物组合物包含第一种活性药物成分（如安眠酮）和第二种活性药物成分（如奥沙西泮）。组合物的结构可以限制第一和第二活性药物成分之间的物理接触，从而防止活性药物成分因两种成分之间的相互作用而降解。组合物可包括至少一种药学上可接受的赋形剂。此外，还提供了组合物的制造方法以及含有提供组合物所需材料的试剂盒。
• Triple drug therapy for the treatment and prevention of acute or chronic pain
  申请人：——

  公开号：US20020058656A1

  公开（公告）日：2002-05-16

  A triple drug therapy, pharmaceutical kit, composition, and method of treatment regimen utilized as a combination of effective amounts of an anxiolytic agent, centrally acting alpha antiadrenergic agent, and central nervous system stimulant for the reduction or prevention of dizziness, drowsiness, depression, delirium, lethargy, mania, orthostatic hypotension, restlessness, weakness in the extremities, and difficulty in being mobile negative side effects caused by therapeutic agents utilized in the treatment of acute and chronic pain syndromes.

  一种三联药物疗法、药用试剂盒、组合物和治疗方法，利用有效量的抗焦虑剂、中枢作用α-抗肾上腺素能剂和中枢神经系统兴奋剂的组合，减少或预防治疗急性和慢性疼痛综合征的治疗剂引起的头晕、嗜睡、抑郁、谵妄、嗜睡、躁狂、正性低血压、烦躁不安、四肢无力和行动困难等不良副作用。